Shire Pharmaceuticals has revised the summary of product characteristics for Maxolon (metoclopramide) 10mg tablets, injection 10mg/2ml, paediatric liquid 1mg/ml, syrup 1mg/ml, Maxolon SR capsules and Maxolon high dose solution for intravenous infusion 100mg/20ml. Under the contraindications section, Maxolon should additionally not be used in patients with phaeochromocytoma, during the first three to four days following operations such as pyloroplasty or gut anastomosis, or in patients with gastrointestinal obstruction, perforation or haemorrhage. The special warnings section has also been extended. Care should be exercised in epileptic patients and patients with porphyria and special care should be taken in cases of hepatic insufficiency. Opioid analgesics, aspirin and paracetamol have been added to the interactions section. Statements referring to co-administering Maxolon with phenothiazines, tetrabenazine, drugs acting at central dopamine receptors, such as levodopa, bromocriptine and pergolide, and atovaquone have also been added. Maxolon should not be used during lactation. Both the undesirable effects and overdose sections have also been updated. The posology and methods of administration section for the Maxolon high dose preparation additionally gives guidance for elderly patients and young adults and children.